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Broadly neutralizing antibodies are commonly present in the sera of patients with chronic hepatitis C virus
(HCV) infection. To elucidate possible mechanisms of virus escape from these antibodies, retrovirus particles
pseudotyped with HCV glycoproteins (HCVpp) isolated from sequential samples collected over a 26-year period
from a chronically infected patient, H, were used to characterize the neutralization potential and binding
affinity of a panel of anti-HCV E2 human monoclonal antibodies (HMAbs). Moreover, AP33, a neutralizing
murine monoclonal antibody (MAb) to a linear epitope in E2, was also tested against selected variants. The
HMAbs used were previously shown to broadly neutralize HCV and to recognize a cluster of highly immuno-
genic overlapping epitopes, designated domain B, containing residues that are also critical for binding of viral
E2 glycoprotein to CD81, a receptor essential for virus entry. Escape variants were observed at different time
points with some of the HMAbs. Other HMAbs neutralized all variants except for the isolate 02.E10, obtained
in 2002, which was also resistant to MAb AP33. The 02.E10 HCVpp that have reduced binding affinities for all
antibodies and for CD81 also showed reduced infectivity. Comparison of the 02.E10 nucleotide sequence with
that of the strain H-derived consensus variant, H77c, revealed the former to have two mutations in E2, S501N
and V506A, located outside the known CD81 binding sites. Substitution A506V in 02.E10 HCVpp restored
binding to CD81, but its antibody neutralization sensitivity was only partially restored. Double substitutions
comprising N501S and A506V synergistically restored 02.E10 HCVpp infectivity. Other mutations that are not
part of the antibody binding epitope in the context of N501S and A506V were able to completely restore
neutralization sensitivity. These findings showed that some nonlinear overlapping epitopes are more essential
than others for viral fitness and consequently are more invariant during earlier years of chronic infection.
Further, the ability of the 02.E10 consensus variant to escape neutralization by the tested antibodies could be
a new mechanism of virus escape from immune containment. Mutations that are outside receptor binding sites
resulted in structural changes leading to complete escape from domain B neutralizing antibodies, while
simultaneously compromising viral fitness by reducing binding to CD81.
Over 170 million people worldwide are infected with hepatitis
C virus (HCV). While acute infection is usually silent, the major-
ity of infected individuals develop persistent infections. Approxi-
mately 30% of acute infections are spontaneously resolved. Cel-
lular immunity is clearly necessary, as robust and sustained CD4
and CD8 T-cell responses are temporally associated with virus
clearance leading to disease resolution (7). Persistent infection is
associated with an inability to sustain a vigorous CD4 response.
The role of antibodies in disease resolution is increasingly recog-
nized but less understood. Clinical trials with gamma globulin
administration prior to the discovery of HCV achieved prophy-
lactic effects on transfusion-associated non-A, non-B hepatitis
cases, most of which were subsequently shown to be HCV related
(28, 46). Animal studies showed that gamma globulin therapy
delayed the onset of acute HCV infection (29). Preincubation of
the infectious inoculum with pooled gamma globulin from HCV-
positive donors prevented infection in challenged chimpanzees
(55). The protection afforded by gamma globulin preparations
correlated with antibody titers blocking infection of target cells
with retroviral pseudotype particles expressing HCV E1E2 glyco-
proteins (HCVpp) (4). In addition, chimpanzees vaccinated with
recombinant HCV E2 glycoproteins were protected against in-
fection in a manner that correlated with serum antibody titers
inhibiting binding of E2 to CD81 (19, 40, 41), a receptor required
for entry by both HCVpp and cell culture infectious HCV
(HCVcc) (5, 17, 33, 53, 56). Two recent studies observed that
patients with strong and progressive neutralizing antibody re-
sponses demonstrated decreasing viremia and control of viral
replication (31, 39). A third study, however, reported the lack of
neutralizing antibodies to heterologous HCVpp isolates in the
sera of patients who eventually controlled their viremia during
acute HCV infection (21). Furthermore, 104 to 106 virions per
milliliter of serum are usually detected during chronic infection in
the presence of high titers of serum neutralizing antibodies.
A driver of persistent viremia is a high degree of viral vari-
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ants, or “quasispecies.” Owing to a high viral replication rate
(1012 copies per day) and an error-prone viral RNA-dependent
polymerase, the estimated mutation rate is 2.0  103 base
substitutions per genome per year (9, 34). This high rate of
quasispecies formation contributes to the emergence of escape
viral variants from immune surveillance. Mutations within ma-
jor histocompatibility complex class I-restricted HCV epitopes
lead to escape from cytotoxic T-cell responses (7). Mutations
leading to escape from humoral immunity, particularly in E2
hypervariable region 1 (HVR1), known to be the target of host
neutralizing antibodies, are also documented (10, 22, 30, 45).
Protection in chimpanzees is achieved following challenge with
an inoculum that had been preincubated with antibodies to
autologous HVR1 (10). Yet over time, these isolate-specific
antibodies drive the emergence of new viral variants that the
concurrent immune response poorly recognizes. A study of
sequential HCV isolates obtained from a patient, H, who was
meticulously followed for a 26-year period starting 3 weeks
after exposure to the virus, showed that the serial HCV vari-
ants were poorly neutralized by the concurrent serum antibod-
ies (52). Escape was associated in part with mutations in HVR1
leading to decreased binding and neutralization by monoclonal
antibodies (MAbs) to HVR1 that were produced against the
first isolate obtained from this patient.
Broadly neutralizing antibodies are usually directed against
conformational epitopes within E2 (2, 8, 13, 14, 44). We pre-
viously described a panel of neutralizing and nonneutralizing
human MAbs (HMAbs) to conformational epitopes on HCV
E2 that were derived from peripheral B cells of individuals
infected with either genotype 1a or 1b HCV. Cross-competi-
tion analyses delineated at least three immunogenic clusters of
overlapping epitopes with distinct functions and properties
(23–25). All nonneutralizing antibodies fell within one cluster,
designated domain A (24). Neutralizing HMAbs segregated
into two clusters, designated domains B and C, with domain B
HMAbs having greater potency than domain C HMAbs in
blocking infection with the strain JFH1 genotype 2a HCVcc
(23, 25).
The epitopes of increasing numbers of anti-HCV E2 neu-
tralizing antibodies include residues that are also critical for
binding of E2 to CD81. All of our domain B HMAbs inhibit
binding of E2 to CD81. Alanine scanning mutagenesis of E2
regions implicated in binding to CD81 identified two highly
conserved residues, G530 and D535, that are needed for all
domain B antibodies, with a subset also requiring W529 (25,
26, 36). Other laboratories have isolated similar neutralizing
antibodies to epitopes containing these residues (20, 32, 38). A
similar panel of E2 mutants was previously used to identify five
amino acid residues, W420, Y527, W529, G530, and D535, that
are essential for interaction with CD81 (37, 42). These findings
show that domain B antibodies exert their potent neutraliza-
tion of HCV infectivity by directly competing with CD81 for
binding to E2. It also explains the breadth of neutralization
against different HCV genotypes and subtypes for many of
these antibodies, since any changes in their epitopes could
affect CD81 binding and virus entry. The conserved nature of
this cluster of overlapping epitopes makes them of interest for
vaccine and immunotherapeutic development. A critical ques-
tion involves the likelihood that immune selection could lead
to escape from neutralization by domain B HMAbs. The series
of sequential HCVpp variants derived from patient H over a
span of 26 years (52) provide a unique resource for studying
the extent and mechanisms of virus escape from broadly neu-
tralizing antibodies. This report describes evidence of escape
from immune containment of some but not other domain B
HMAbs. Interestingly, a single H variant with reduced HCVpp
infectivity and diminished CD81 binding was resistant to neu-
tralization by all domain B antibodies as well as MAb AP33,
recognizing a highly conserved linear epitope spanning resi-
dues 413 to 420 (35, 47). Sequence analysis revealed multiple
mutations on E2 at a considerable distance from CD81 binding
residues that could account for the immune escape, although it
is unlikely that they are part of the domain B HMAb or the
AP33 epitopes. Site-directed substitutions at these mutations
restored neutralization sensitivity to all antibodies and CD81
dependency.
MATERIALS AND METHODS
Cell culture, antibodies, and reagents. HEK-293T cells were obtained from
the ATCC. Huh7.5 cells (6) were grown in Dulbecco’s modified minimal essen-
tial medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum
(Sigma-Aldrich Co., St. Louis, MO) and 2 mM glutamine. HMAbs CBH-2,
CBH-5, CBH-8C, CBH-11, HC-2, and HC-11 and MAb AP33 against HCV E2
were generated as described previously (14, 23, 35). MAb against human CD81
(clone JS-81) was purchased from BD Bioscience (San Jose, CA). A molecular
clone encoding the CD81 large extracellular loop fused to glutathione S-trans-
ferase was generously provided by Shoshana Levy (Stanford University) and
affinity purified over a GSTrap FF affinity column according to the manufactur-
er’s instructions (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). A series of
plasmids encoding H77c E1E2 variants derived from patient H sera obtained
between 3 weeks postinfection and throughout the subsequent 26 years thereaf-
ter were constructed as described previously (52). The plasmids were designated
aa.bb, where aa denotes the year of serum sample collection and bb denotes the
clone number. For example, 02.E10 represents HCV RNA that was isolated from
a plasma sample collected in 2002 and the E10 clone represents the consensus
sequence among multiple clones obtained from 2002.
HCVpp production, infection, and neutralization assay. HCVpp were pro-
duced as described previously (17, 24) by cotransfection of 293T cells with
plasmids containing the env-defective proviral genome and an expression plas-
mid encoding the HCV glycoproteins. The virus-containing extracellular medium
was collected 48 h after transfection and separated from cell debris by passing
through a 0.45-m filter. For the neutralization assay, the virus-containing me-
dium was incubated with each HMAb or phosphate-buffered saline instead of the
antibodies as an infectivity control plus 4 g/ml polybrene at 37°C for 60 min.
The HCVpp-antibody mixture was added to preseeded Huh7.5 cells (8  103
cells/well) in a white nontransparent 96-well plate. For blocking of virus entry by
anti-CD81, the cells with preincubated for 1 h with the mouse antibody prior to
the addition of HCVpp. The plate was centrifuged at 730  g for 2 h at room
temperature before being placed in a humidified cell culture chamber containing
5% CO2 at 37°C. Unbound virus was replaced with fresh complete medium, and
then the plates were incubated for a total of 72 h. After addition of 100 l of
reconstituted Bright-Glo (Promega) to each well, followed by mixing for 2 min at
room temperature, luciferase activity was measured by a Veritas microplate
luminometer (Turner Biosystems). The virus neutralization activity of an anti-
body was determined by the percent reduction of luciferase activity compared
with the level for the phosphate-buffered-saline control. For HCVpp infectivity
studies, the virus-containing extracellular medium was normalized for human
immunodeficiency virus p24 expression by using a QuickTiter lentivirus titer kit
(Cell Biolabs, San Diego, CA) in accordance with the manufacturer’s instruc-
tions.
The transfected 293T cells was lysed with a buffer containing 10 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 1% NP-40, 20 mM iodoacetamide, and protease inhibi-
tors. The lysates were used as the source of E2 antigen at approximately 225
ng/ml in the immunoassays as described below.
Quantitative enzyme-linked immunoassays. Microtiter plates were prepared
by coating each well with 500 ng of Galanthus nivalis lectin (GNA; Sigma, St.
Louis, MO), followed by blocking of the wells with BLOTTO, consisting of 2.5%
nonfat dry milk and 2.5% normal goat serum in TBST (20 mM Tris-HCl, pH 7.5,
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150 mM NaCl, 0.1% Tween 20). For antibody affinity analysis, lysates of 293 cells
expressing HCV E1E2 as described above were first captured on the GNA-
coated plates. The bound antigens were then incubated with HMAb to HCV E2
at concentrations of 0, 0.05, 0.2, 1, 5, 20, 100, and 200 g/ml. After a wash, the
bound antibodies were then visualized with AP-conjugated goat anti-human
immunoglobulin G (IgG; Santa Cruz Biotechnologies, Santa Cruz, CA) and
developed using p-nitrophenyl phosphate disodium hexahydrate. Absorbance
was measured at 405 nm and 570 nm using a Spectra Max 190 plate reader
(Molecular Devices, Sunnyvale, CA). The data were analyzed by nonlinear re-
gression to measure the antibody disassociation constant (Kd) and the max-
imum binding level (Bmax) (optical density at 405 nm), using Prism software
(GraphPad).
For CD81 binding analysis, 20% sucrose cushion-pelleted HCVpp were re-
suspended in NTE buffer (150 mM NaCl, 1 mM EDTA, 10 mM Tris-HCl, pH
7.4) and captured on the GNA-coated plates. Bound antigen was first incubated
with purified CD81 at concentrations of 0, 0.5, 1.0, 2.0, 10, 20, 50, 100, 200, and
500 g/ml. The bound CD81 was visualized with AP-conjugated mouse anti-
human CD81 (Santa Cruz Biotechnologies, Santa Cruz, CA). Color development
and absorbance measurement were performed as described above.
In vitro mutagenesis. All mutagenesis was conducted using a QuikChange II
site-directed mutagenesis kit (Agilent, La Jolla, CA) in accordance with the
manufacturer’s instructions. A plasmid containing the 02.E10 variant (GenBank
accession no. DQ897814) E1E2-encoding sequence was used as the template for
initial single mutations and then as the template for introduction of double
mutations. The triple mutations were constructed sequentially in the context of
the double mutations. All the mutations were confirmed by DNA sequence
analysis (Sequetech, Mountain View, CA) for the desired mutation and for
exclusion of unexpected residue changes in the full-length E1E2 encoding se-
quence. The mutated constructs were designated X#Y, where # is the residue
location in H77c (GenBank accession no. AF009606), X denotes the single-letter
code for the H77c or 02.E10 amino acid, and Y denotes the altered amino acid.
RESULTS
Patient H, followed for a 26-year period starting 3 weeks
after exposure to HCV, has had a clinical course of mild and
nonprogressive chronic hepatitis typical of most patients with
HCV infection (52). Earlier studies showed that his chronic
infection continuously generated quasispecies that were poorly
neutralized by the concurrent serum antibodies. While the
persistent viremia can be explained in part by escape from
neutralizing antibodies to HVR1, cross-neutralizing serum an-
tibodies were observed beginning at week 111 after infection in
patient H. This raises questions regarding the extent to which
chronic infection leads to quasispecies that are able to evade
broadly neutralizing antibodies and the identity of the mech-
anisms that contribute to such escape.
Profiling of binding of neutralizing antibody to E2 variants.
Six neutralizing HMAbs to overlapping epitopes within E2
domain B were selected to test for binding to sequential E2
samples obtained from patient H (52). This was performed
using lysates from transfected cells expressing wild-type H77c
and variant E1E2 polyproteins that were captured onto GNA-
coated enzyme-linked immunosorbent assay (ELISA) plates.
Each antibody was tested at dilutions ranging from 0.1 to 100
g/ml (Table 1). R04, a human Ig isotype control HMAb to
human cytomegalovirus, showed no binding to either H77c or
the other H variants. Of the six anti-E2 antibodies, only three,
CBH-5, HC-2, and HC-11, bound to H77c E2. Interestingly, all
six antibodies showed low-minimum binding (HC-11  HC-2
 CBH-8C  CBH-5  CBH-2) to no binding (CBH-11) to
02.E10 E2, a dominant variant isolated at the 26th year after
acute infection. With 02.E10 set aside, four binding patterns
emerged. The first pattern, represented by CBH-11, was failure
to bind to H77c and all of the variants. The second binding
pattern, displayed by CBH-2 and CBH-8C, showed binding to
the sequential variants, beginning with those collected in 1991.
The antibody Kds for these variants ranged from 63.4 to 270.9
nM and from 40.5 to 71.4 nM, respectively. The third binding
pattern, represented by CBH-5, showed binding to all variants
but had lower Kds for the 1977 isolates (131.3 to 424.7 nM)
than for the subsequent sequential variants (6.9 to 20.3 nM).
The fourth binding pattern, represented by HC-2 and HC-11,
showed binding to all variants, including H77c, and had a
tighter range of Kds, which were from 4.4 to 23.4 nM and 9.9 to
44.3 nM, respectively. Taken together, the variants showing
altered binding affinities for individual antibodies at different
years from 1977 to 1995 suggest that the virus might continu-
ously mutate within E2 regions as defined by these domain B
antibodies. However, the 02.E10 variant isolated at the last
sampling point showed low to no binding by all domain B
antibodies tested. This variant, in comparison to H77c, also
showed reduced binding by MAb AP33 (see Fig. 5B), which is
in agreement with earlier findings with MAb 3/11 recognizing
a similar epitope on E2 (11, 35, 50, 52). In addition, these two
murine antibodies exhibit no cross-competition with any do-
main B antibodies (data not shown). The findings suggest that
the 02E10 variant might have undergone a structural change
that negatively modulates binding by the antibodies to over-
lapping conformational epitopes within domain B as well as to
two nonoverlapping linear epitopes on E2. These antibodies
TABLE 1. Neutralization and antibody binding affinity for sequential patient H variantsa
Variant
CBH-11 CBH-2 CBH-8C CBH-5 HC-2 HC-11 R04
IC50 Kd IC50 Kd IC50 Kd IC50 Kd IC50 Kd IC50 Kd IC50 Kd
H77C NR NB NR NB NR NB 82.5 131.3 1.2 4.4 2.1 12.1 NR NB
77.19 NR NB NR NB NR NB NR 424.7 13.6 19.6 6.7 44.3 NR NB
77.20 NR NB NR NB NR NB 29.8 298.5 2.8 9.2 4.1 21.8 NR NB
91.64 NR NB NR 108.2 42.0 40.5 4.3 10.1 12.7 11.9 16.5 10.7 NR NB
91.A6 NR NB 95.3 78.7 9.0 43.7 3.5 7.9 4.3 13.6 2.9 15.6 NR NB
91.A11 NR NB 71.1 270.9 67.0 50.3 10.9 11.3 4.0 18.4 35.8 18.5 NR NB
91.B1 NR NB NR 63.4 98.0 47.6 19.8 6.9 27.0 13.2 18.6 9.9 NR NB
92.C1 NR NB NR 189 46.5 71.4 17.2 20.3 14.1 23.2 9.3 25.7 NR NB
95.C8 NR NB 79.5 148.5 15.5 59 14.9 21 3.8 23.4 6.6 32.1 NR NB
02.E10 NR NB NR 216.5 NR 106.3 NR 131.5 NR 55.7 NR 37.3 NR NB
a Plasmids encoding HCV variant E2 glycoproteins are designated aa.bb, where aa denotes the year of serum sample collection and bb denotes the clone number
(52). IC50s are in g/ml, and Kds are in nM. NR, not reaching 50% neutralization; NB, no binding.
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share a common mechanism of virus neutralization by blocking
virus binding to CD81.
Neutralization of the sequential HCV variants. To assess
whether the binding patterns of the tested antibodies corre-
lated with neutralization, antibody dose-dependent studies
were performed using HCVpp consisting of E1E2 variants
assembled onto retroviral core particles. Four neutralization
patterns that paralleled the antibody binding patterns were
observed. As shown in Fig. 1 and summarized in Table 1, H77c
and all of the variants escaped from CBH-11 neutralization in
the first pattern. Low neutralizing activity against 02.E10 was
observed, but without a dose-dependent effect. In the second
pattern, the 1977 isolates failed to be neutralized by CBH-2
and CBH-8C. Neutralization was observed for CBH-8C start-
ing with the 1991 variants and the subsequent variants through
1995, but not for CBH-2, where decreased neutralizing activity
was observed for the 1992 variant. The 50% inhibitory concen-
trations (IC50s) ranged from 0 to 95.3 g/ml for CBH-2 and
from 9.0 to 98.0 g/ml for CBH-8C. CBH-5 showed a third
neutralization pattern, with lower neutralization potency for
H77c (IC50 at 82.5 g/ml) and no neutralization with one of
the 1977 isolates but high activities against the 1991-to-1995
variants (IC50s at 3.5 to 19.8 g/ml). HC-2 and HC-11 dis-
played a fourth pattern, with relatively sustained neutralization
activities against H77c and all of the variants from 1977 to
1995. The IC50s ranged from 1.2 to 27.0 g/ml for HC-2 and
from 2.1 to 35.8 g/ml for HC-11. The different neutralization
patterns confirm our previous observation that the six domain
B antibodies recognize overlapping but distinct epitopes. Each
of these epitopes contains residues that are also involved in
binding of E2 to CD81 and other antibody-specific residues
that are discontinuous from the CD81 binding region (25–27).
Neutralization studies with each antibody against 02.E10
HCVpp showed no dose-dependent effect and produced gen-
erally weak responses, with a maximum of 40% neutralization.
The 02.E10 variant was resistant to CBH-5, HC-2, and HC-11
in comparison to H77c HCVpp and also resistant to CBH-2
and CBH-8C in comparison to the 95.C8 HCVpp. These find-
ings are consistent with the loss in binding to the 02.E10 vari-
ant by all domain B antibodies. In the course of these studies,
we noted that the 02.E10 HCVpp infectivity was very low,
which contributed to unreliable measurements of neutraliza-
tion, as shown by the lack of a dose-dependent effect with
CBH-8C and CBH-11. The breadth of antibody escape by
variant 02.E10 implies that the location of the mutation or
mutations caused a change in the conformational structure of
E2 in relationship to the epitopes identified by this group of
neutralizing antibodies.
Sequence analysis of E2-carrying variants. To assess the
sequence variation associated with the broad neutralization
escape and low infectivity shown by the 02.E10 variant, the E2
sequences from all of the H variants were compared (Table 2)
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FIG. 1. Neutralization profiles for sequential HCVpp H77c E1E2 variants obtained from the sera of a patient, H, collected during a 26-year
period of mild chronic HCV infection (52). Various HCVpp (shown on the x axis) were preincubated with different concentrations of each HMAb,
as indicated (y axis), at 37°C for 1 h prior to infection of Huh7.5 cells. Neutralization of each tested antibody is expressed as percent reduction of
luciferase activity compared to the level for the no-antibody control (z axis). The variants are designated aa.bb, where aa denotes the year of serum
sample collection and bb denotes the clone number.
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based on the published sequences (52). Analysis revealed 25
amino acid changes that are outside the HVR1 region among
the variants in relationship to the reference H77c isolate
(GenBank accession no. AF009606). The mutations can be
divided into four groups on the basis of what year they were
identified in and whether the mutation was maintained
throughout the remaining years of observation. The first group
(type 1) contains mutants that emerged by 1991 and were fixed
for the remaining years (mutations E431D, T435A, A466D,
S528N, A531E, V538I, L580R, D610H, V636I, and A713T). In
the second group (type 2), mutations were introduced in var-
ious isolates but not in the 02.E10 variant (at residues N415,
L438, P453, D481, Y489, F537, I622, and V720) or were in
02.E10 and also other variants (at residues L480 and I626).
The third group (type 3) contains mutations that are similar in
pattern to the first group and were present in 1991 but main-
tained only through 1995, and then two new mutations were
found in 2002 (Q444H and K446G). Finally, the fourth group
(type 4) contains 2002 variant-specific mutations (E482Q,
S501N, and V506A). Since we observed previously that S501
and V506 are located in a region that is crucial in maintaining a
native E2 structure (18), we reasoned that the amino acid substi-
tutions of the type 4 group most likely contribute to the observed
phenotypes of the 02.E10 variant, followed by type 3 substitutions.
Mutations responsible for reduced 02.E10 variant infectiv-
ity. To assess which of the five type 3 and 4 amino acid changes
in the 02.E10 variant led to reduced infectivity and/or the
neutralization-resistant phenotype, we introduced substitu-
tions at each site either individually or jointly in the 02.E10
clone (Fig. 2A). Each substitution was based on the corre-
sponding residue in an earlier H variant or in H77c. The
mutant 02.E10 E1E2 was then incorporated into HCVpp, and
its infectivity was compared to that for H77c. HCVpp infection
of Huh7.5 cells was quantified by a luciferase assay. As shown
in Fig. 2A, substitutions Y444H, Y444Q, R446K, R446G,
Q482E, and N501S in 02.E10 E2 were unable to significantly
increase 02.E10 infectivity, indicating that they were not re-
sponsible for the reduced infectivity of the 02.E10 variant. In
contrast, A506V substitution restored 50% infectivity com-
pared to the level for H77c. The mutation at residue 501, being
in close proximity to residue 506, could compound the struc-
tural effects of a mutation at residue 506, which prompted us to
introduce the double mutations (N501S/A506V) into HCVpp
02.E10 E2. Indeed, infectivity was restored to the levels of
H77c HCVpp. Taken together, the substitutions at residues
444, 446, and 482 in 02.E10 have no role in viral infectivity, but
introduction of substitutions at residues 501 and 506 restored
the infectivity of the 02.E10 variant. It is probable that the
proximity of this pair of mutations is a contributing factor in
their effect on the E2 structure. To confirm these findings,
alanine substitutions at these five residues were introduced
TABLE 2. Sequence analysis of amino acid differences in the HCV E2 glycoproteins of H77c and variants outside HVR1a
41
5
43
1
43
5
43
8
44
4
44
6
45
3
46
6
48
0
48
1
48
2
48
9
50
1
50
6
52
8
53
1
53
7
53
8
58
0
61
0
62
2
62
6
63
6
71
3
72
0
N E T L Q K P A L D E Y S V S A F V L D I I V A V
N E T L Q K P A P G E C S V S A F V L N I I V A V
N E T L Q K P A L D E Y S V S A F V L D I I V A V
N D A L H G P D P D E Y S V N E L I R H T I I A V
N D A L H G P D P D E Y S V N E L I R H I I I T V
N D A L H G P D P D E Y S V N E L I R H I I I T V
N D A L H G P D P D E Y S V N E L I R H I V I T V
K D A I H G T D P D E Y S V N E L I R H I I I T A
K D A I H G T D P D E Y S V N E L I R H I I I T V
N D A L Y R P D P D Q Y N A N E F I R H I V I T V
A.A. Location
H77c
H77 319 
H77 320
H91 64
H91 A6
H91 A11
H91 B1
H92 C1
H95 C8
H02 E10
a Type 1 (yellow), 2002 residues that are identical, with H91, H92, and H95 variants, but with an exception in one 1991 variant (A/T) at position 713; type 2 (purple),
mutations in specific variants but not in the 2002 variant or mutations in both 2002 and other variants; type 3 (green), 2002-specific mutations, but with H77c being
different from H91, H92, and H95 variants at residues 444 and 446; type 4 (red), 2002-specific mutations.
FIG. 2. (A) Infectivity of HCVpp bearing various reverse muta-
tions in E2 of the 02.E10 variant. HCVpp incorporating H77c or
various substitution mutants of 02.E10 envelope glycoproteins were
normalized to p24 expression levels and used to infect Huh7.5 cells. At
72 h postinfection, virus infectivity was determined by measuring lu-
ciferase activity. RLU, relative luciferase units. (B) Infectivity of H77c
HCVpp bearing various mutations in E2 was tested as described for
panel A.
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individually in the H77c construct (Fig. 2B). We observed that
substitutions at residues 444, 446, and 501 decreased H77c
HCVpp infectivity modestly and that substitution at residue
482 slightly increased infectivity, but H77c HCVpp bearing
V506A decreased infectivity by more than 90%.
Mutations at residues 501 and 506 modulate E2-CD81 in-
teraction. As the S501N/V506A mutations had a significant
impact on 02.E10 HCVpp infectivity, we tested whether these
mutations adversely affected the virus interaction with CD81.
This in turn could account for the inefficient cell entry as
displayed by the 02.E10 variant, relative to the levels for H77c
and the other H variants (Fig. 2A). We investigated the effect
of the double mutations on the binding of the virus to CD81.
This was assessed by evaluating the ability of anti-CD81 to
inhibit variant and mutant HCVpp entry and by determining
the binding of the mutant E2 to CD81. As shown in Fig. 3A,
pretreatment of Huh7.5 cells with anti-CD81 antibody inhib-
ited H77c HCVpp infection by 90% but only 20% inhibition
was observed for the 02.E10 HCVpp. A control without anti-
body was used as the baseline for each variant, again showing
low infectivity for the 02.E10 HCVpp, as observed in Fig. 2A.
Interestingly, anti-CD81 antibody inhibited infection by 02.E10
HCVpp bearing N501S/A506V mutations as efficiently as
H77c, indicating that residues 501 and 506 in combination may
contribute to the maintenance of the structural conformation
for E2 that is optimum for its interaction with CD81. Isotype-
matched control antibodies did not specifically reduce HCVpp
infection (data not shown).
We next analyzed the binding disassociation constants of
various E2 variants to CD81 by ELISA. As shown in Fig. 3B,
C, and D, CD81 bound approximately fourfold less to 02.E10
E2 than to both H77c E2 and the N501S/A506V-02.E10 E2
variant, with Kds of 6.32, 1.53, and 1.72 M, respectively. But
the Bmax values for binding of CD81 to all three E2 variants
were relatively consistent, with values of 0.41 to 0.54, suggest-
ing that the incorporations of envelope proteins were nearly
equal among these variants. The observation that the binding
affinity of 02.E10 E2 for CD81 was decreased but that the Bmax
was similar to that for binding of CD81 to H77c and to N501S/
A506V-02.E10 E2 is consistent with the view that substitutions
at residues 501 and 506 caused a structural alteration of the
E2-CD81 binding region. To ensure that 02.E10 HCVpp entry
was occurring, since this variant showed a low luciferase (in-
fectivity) reading, maximum blocking of entry with anti-CD81
was performed. Anti-CD81 blocked 02.E10 HCVpp entry
more than 25% compared to the level for a vector control (data
not shown). These studies collectively showed that the mechanism
of escape by the 02.E10 variant from neutralizing antibodies is by
negatively modulating the virus interaction with CD81.
FIG. 3. Substitutions S501N/V506A in the context of the 02.E10
variant compromise binding of HCVpp to CD81. (A) Blocking of
HCVpp infectivity by anti-CD81. Huh7.5 cells were preincubated with
5 g/ml of anti-CD81 prior to infection with HCVpp bearing H77c,
02.E10, and 02.E10-N501S/A506V E2 envelope proteins. The control
for each variant was without anti-CD81. The results are expressed as
percentages of neutralization relative to the level for a no-antibody
control for each variant or mutant, as measured by luciferase activity.
N501S/A506V 02.E10 envelope protein to CD81 by ELISA. The bind-
ing measurements were performed using 20% sucrose cushion pellet
HCVpp. GNA-captured HCVpp were incubated with a range (0.01 to
500 g/ml) of CD81 (x axis), and the bound receptor was detected
using an anti-CD81 MAb. The y axis shows the mean optical density
(OD) values for triplicate wells representing bound CD81. Error bars
represent 1 standard deviation from the mean. The saturation binding
curves were fit by nonlinear regression. Kd (M) and Bmax values were
calculated using GraphPad Prism software, and Scatchard plots of the
equilibrium binding data are shown in the insets.
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Effect of S501N/V506A mutations on antibody-mediated
neutralization. Since N501S/A506V restored 02.E10 infectivity
by restoring E2-CD81 binding to a level similar to that for
H77c, we next investigated whether mutations S501N/V506A
are also responsible for the ability of the 02.E10 variant to
escape from neutralizing antibodies (Fig. 4 and 5B). First, five
domain B HMAbs and MAb AP33 were assessed for their
binding affinities for 02.E10 E2 carrying N501S/A506V substi-
tutions. CBH-11 was not included, because it failed to bind and
neutralize H77c and all of the sequential variants (Fig. 1).
Interestingly, CBH-5 and HC-11 had lower Kds for N501S/
A506V-02.E10 E2 (6.2 and 7.8 nM, respectively) than for H77c
(131.3 and 12.1 nM, respectively) or for 02.E10 E2 (131.5 and
37.3 nM, respectively), as summarized in Fig. 5B. In the cases
of CBH-2 and CBH-8C, reduced Kds (71.1 and 49.4 nM, re-
spectively) were also obtained in comparison to those for their
binding to either 95.C8 E2 (148.5 and 59 nM, respectively)
(Table 1) or 02.E10 E2 (216.5 and 106.3 nM, respectively).
Note that these two antibodies do not bind to H77c. HC-2 had
a binding affinity for 02.E10 E2 carrying N501S/A506V substi-
tutions (Kd, 11.9 nM) that was lower than that for H77c (Kd, 4.4
nM) but higher than that for 02.E10 E2 (Kd, 55.7 nM). The
AP33 binding disassociation constant remained similar to
those for 02.E10 E2 and 02.E10 E2 carrying N501S/A506V
substitutions (Kds of 5.0 and 5.5 nM, respectively), which were
higher than that for H77c (Kd, 1.7 nM). Taken together, the
binding affinities of the antibodies for the E2 conformational
epitopes CBH-2, CBH-8C, CBH-5, HC-2, and HC-11 were
improved 3.0-, 2.1-, 21.1-, 4.7-, and 4.8-fold, respectively, by
N501S/A506V substitutions in the 02.E10 variant. As residues
501 and 506 are not known to be part of the epitopes identified
by these antibodies, the findings are consistent with the view
that residues 501 and 506 affect the E2 conformational struc-
ture required for these antibodies to bind to E2 as well as for
E2 to bind to CD81.
Next, we assessed whether these antibodies showed im-
FIG. 4. Effect of the N501S/A506V substitutions on restoring antibody-mediated neutralization. Neutralization with HCVpp bearing H77c,
02.E10, or N501S/A506V 02.E10 envelope proteins was performed as described in the legend to Fig. 1. HCVpp were preincubated with each
HMAb, as indicated, at 37°C for 1 h at the specified concentrations, as shown on the y axis, prior to infection of Huh7.5 cells. Neutralization of
the tested antibody is expressed on the z axis as percent reduction of luciferase activity relative to the level for a no-antibody control. On the x axis,
the H77c, tested variants, and reverse-mutated variant are indicated. Variant 95.C8 is included as a binding reference in the top panels since the
indicated antibodies failed to bind to H77c.
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proved neutralizing activities against 02.E10 HCVpp bearing
N501S/A506V E2. H77c or 95.C8 HCVpp was used for com-
parison against appropriate antibodies. As shown in Fig. 4,
N501S/A506V-02.E10 HCVpp exhibited dose-dependent neu-
tralization by all antibodies tested. In comparison, 02.E10
HCVpp showed no consistent dose-dependent neutralization.
However, recovery of neutralization activities against N501S/
A506V-02.E10 HCVpp was only 30 to 40% for all five domain
B HMAbs, even at an antibody concentration of 100 g/ml,
compared to the level for H77c or the 95.C8 variant. In the
case of AP33, the IC50 for wild-type H77c HCVpp was 0.7
g/ml (Fig. 5B). For 02.E10 HCVpp, only 20% neutralization
was observed at 100 g/ml (Fig. 4), and for the N501S/A506V-
02.E10 HCVpp, the IC50 was 8.8 g/ml (Fig. 5B). Although
N501S/A506V restored 90% AP33 neutralization at 100
g/ml compared to the level for H77c, the IC50 indicates only
partial restoration. While substitutions S501N/V506A are re-
sponsible for the loss in the binding of domain B antibodies to
the 02.E10 variant, they can account for only partial restora-
tion of the neutralization activities of these antibodies to con-
formational epitopes. The findings suggest that other residues
are likely involved in forming the binding pockets for domain
B antibodies to effectively block E2-CD81 interaction.
Effects of other mutations on modulating neutralizing anti-
body potency. The unexpected low neutralization potency in
association with fully recovered binding affinity prompted us to
introduce additional substitutions. Each individual substitution
(Y444Q, Y444H, R446K, R446G, or Q482E) (Table 2) in the
context of N501S/A506V 02.E10 E2 was tested to determine
whether additional residues beyond 501 and 506 could affect
virus neutralization. Although residues Y444, R446, and Q482
are 02.E10 specific but were judged not to contribute to res-
toration of 02.E10 infectivity (Fig. 2), we speculated that they
could, in concert with residues 501/506, adversely affect do-
main B neutralizing antibodies. The substitutions at each of
these residues were based on the corresponding residue lo-
cated in either H77c or a later H variant. Five domain B
antibodies and AP33 were assessed for their abilities to neu-
FIG. 5. Effects of residues 444, 446, and 482 on restoration of antibody neutralization potency. (A) Neutralizations with HCVpp bearing H77c,
02.E10, or single or triple reverse-mutated 02.E10 E2 were performed as described in the legend to Fig. 1. HCVpp were preincubated with CBH-2
or HC-11 at 37°C for 1 h at the concentrations specified on the y axis, prior to infection of Huh7.5 cells. Neutralization by each antibody is expressed
on the z axis as percent reduction of luciferase activity relative to the level for a no-antibody control. On the x axis, the H77c, testing variant, and
reverse-mutated variants are as indicated. (B) HMAb neutralization potency and binding affinity for H77c, 02.E10, and 02.E10 containing single
or triple mutations. The table summarizes the IC50 of each HMAb for H77c and the mutated HCVpp and the Kd for binding of each HMAb to
H77c and the mutated E2 proteins.
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tralize the five N501S/A506V-02.E10 HCVpp bearing Q482E,
Y444Q, Y444H, R446K, or R446G, as summarized in Fig. 5B.
The 02.E10 HCVpp bearing N501S/A506V E2 was used as the
control. The neutralization activities of CBH-2 and HC-11 are
shown as representatives of domain B antibodies in Fig. 5A.
Variant 95.C8 was used as a baseline to assess the relative
neutralization potencies of CBH-2, CBH-8C, and CBH-5. As
shown in Fig. 5A, H77c HCVpp was neutralized by HC-11,
with the IC50 at 2.1 g/ml (Fig. 5B). N501S/A506V-02.E10
HCVpp showed 40% neutralization by HC-11 at 100 g/ml,
whereas the parent, 02.E10, was resistant to neutralization
by this antibody. In contrast, four of the five substitutions,
Y444H, Y444Q, R446G, and R446K of 02.E10 HCVpp
bearing N501S/A506V E2, showed dose-dependent HC-11
neutralizations, with IC50s of 16.9, 3.3, 65.6, and 15 g/ml,
respectively. Introduction of Q482E to N501S/A506V-
02.E10 HCVpp did not result in any improvement in HC-11
neutralization potency, which remained at 45% neutraliza-
tion at an antibody concentration of 100 g/ml. In the case
of CBH-2, the IC50 for variant 95.C8 was 79.5 g/ml (Table
1). N501S/A506V-02.E10 HCVpp was neutralized 36% at an
antibody concentration of 100 g/ml, and CBH-2 was unable
to neutralize 02.E10. Similar to what was found for HC-11,
four of the five substitutions, Y444H, Y444Q, R446G, and
Q428E, showed dose-dependent CBH-2 neutralization in
02.E10 HCVpp bearing N501S/A506V E2, with IC50s of
26.7, 4.8, 80.3, and 7.7 g/ml, respectively. Introduction of
R446K into N501S/A506V-02.E10 HCVpp did not show any
improvement with CBH-2 neutralization potency, which re-
mained at approximately 40% neutralization at an antibody
concentration of 100 g/ml. Similar effects on neutralization
potency were observed for CBH-8C, CBH-5, and HC-2, as
summarized in Fig. 5B. Collectively, substitutions Y444(H/
Q), R446(G/K), and Q482E improved neutralization by
these antibodies, with the exception of Q482E and R446K,
which showed no changes for HC-11- and CBH-2-mediated
neutralizations, respectively. Substitution at residue 444
showed greater improvement in neutralization potency than
the substitutions at residues 446 and 482. Among the sub-
stituted amino acids, replacement with glutamine showed
higher neutralization potency than replacement with histi-
dine. Substitution Y444Q in combination with N501S/
A506V led to a near-complete restoration of 02.E10 sensi-
tivity to neutralization by the tested antibodies. The
infectivity of this mutant was also similar to the level for
H77c. These findings indicate that only in concert with mu-
tations at residues 501 and 506 can a mutation at residue
444, 446, or 482 negatively modulate antibody-mediated
neutralization by a mechanism independent of the epitopes,
as identified by these antibodies.
This possibility was further tested with AP33 against the
Y444H and Y444Q 02.E10 HCVpp bearing N501S/A506V E2
(Fig. 5B). The introduction of Y444Q to HCVpp bearing
N501S/A506V-02.E10 E2 restored AP33 neutralization po-
tency nearly to the same level as that observed with H77c. No
effect was observed with the Y444H mutant. Their IC50s were
1.8 and 9.7 g/ml, respectively, compared to the IC50 of 8.8
g/ml for 02.E10 HCVpp bearing S501N/V506A E2. These
findings confirm that residue 444 is able to negatively modulate
neutralizing antibodies independently of the locations of their
epitopes. As seen in the case of domain B conformational
epitopes, replacing tyrosine with glutamine resulted in greater
improvement than replacing tyrosine with histidine. Although
the mechanism is unclear, these residues in concert with the
mutations at residues 501 and 506 resulted in an alteration of
the E2 structure that affected the potency of neutralizing an-
tibodies without affecting E2-CD81.
DISCUSSION
A majority of broadly neutralizing anti-HCV antibodies
identified to date seem to exert their inhibitory effect by block-
ing E2-CD81 interaction. In this respect, the epitopes of our
neutralizing domain B HMAbs include E2 amino acids W529,
G530, and D535, residues that are also critical for the interac-
tion of E2 with CD81 (37). These residues are also crucial for
recognition by broadly neutralizing human antibodies isolated
in other laboratories (20, 32, 38). Indeed, some of these anti-
bodies have been shown to prevent infection with heterologous
viruses in the human liver chimeric mouse model (32). Anti-
body cross-competition studies show that these residues col-
lectively form a distinct cluster of overlapping epitopes, with
various degrees of conservation among different HCV geno-
types and subtypes (14, 25, 32). Furthermore, removal of an
N-glycan by N532A substitution in E2 leads to enhanced neu-
tralization by a domain B HMAb and sera from individuals
infected with different viral genotypes, indicating that antibod-
ies to domain B epitopes are commonly found during chronic
HCV infection (15). Collectively, these observations confirm
that domain B is a highly immunogenic region on HCV E2,
containing multiple overlapping neutralization epitopes.
If broadly neutralizing antibodies are commonly found dur-
ing chronic infection, what are the mechanisms by which the
virus avoids immune containment? One possibility is that
virion components such as glycans (as mentioned above) or
lipoproteins may provide a protective shield. In the infected
host, HCV can be found as lipid-coated virions and antibody-
complexed virions. Virions primarily associated with low-den-
sity lipoproteins display higher infectivity than higher-density
virions associated with antibodies (16, 48). Furthermore, lower-
density virions during chronic infection are associated with
IgG, IgM, and apolipoprotein B (3), suggesting a modulating
effect of antibody-mediated neutralization. Binding of lipopro-
tein-coated virions to the cellular low-density-lipoprotein re-
ceptor is a candidate pathway of virus entry (1).
In this study, we found different patterns of domain B
epitope evolution in the 26 years of HCV infection in patient
H, providing evidence that immune pressure by domain B-like
antibodies drives the evolution of this virus, leading to greater
viral diversity and different mechanisms of escape. First, the
1977 variants were isolated from the serum of patient H within
3 weeks of exposure to HCV and prior to the development of
serum antibodies to HCV (52). The emergence of early
CBH-2, CBH-8C, and CBH-11 neutralization-resistant vari-
ants could be attributed to the presence of CBH-2-, CBH-8C-,
and CBH-11-like serum antibodies in the original donor of the
HCV-contaminated blood that was transfused to patient H. Of
these three antibodies, CBH-2 has the epitope evolution pat-
tern most analogous to the waxing and waning escape patterns
associated with antibodies to HVR1 (52). It is possible that this
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reflects CBH-2-like serum antibodies in patient H selecting
resistant autologous quasispecies but able to neutralize heter-
ologous isolates. The CBH-2 contact residues G530 and D535
are conserved among all HCV isolates, which explains the
broad neutralizing profile of this antibody against different
genotypes and subtypes (36). But the epitope also includes a
site of variability at residue 431 on E2 that can lead to escape
variants (26). The escape patterns associated with these three
antibodies provide evidence that some antibodies to confor-
mational epitopes that are more conserved among different
genotypes and subtypes do drive a greater level of diversity in
viral variants. Selection of escape variants can occur with a
single-amino-acid substitution within these epitopes, leading to
a high level of neutralization escape without apparent loss of
replication fitness. This is analogous to neutralizing antibodies
directed at HVR1 and explains in part the coexistence of
persistent viremia despite the presence of broadly neutralizing
antibodies in patients with chronic HCV infection. Nonethe-
less, two of the domain B antibodies, HC-2 and HC-11, showed
sustained neutralization of all of patient H isolates from 1977
to 1995. In addition, CBH-5 neutralized all of the isolates
except for one of the two 1977 variants. These sustained neu-
tralization patterns raise the possibility that their epitopes
could contain residues that are less susceptible to sequence
variation because of their functional role in receptor binding or
other associated steric constraints. If this is the case, the in-
clusion of these epitopes will be important in vaccine develop-
ment since the likelihood of inducing escape mutations is re-
duced. It is also possible that the CBH-5, HC-2, and HC-11
epitopes are not immunogenic, leading to the lack of elicitation
of these antibodies in this patient during chronic infection.
However, this is unlikely, since domain B epitopes are highly
immunogenic and commonly found during chronic HCV in-
fection. The patient H sera from which the sequential variants
were isolated are unfortunately no longer available for further
testing.
As shown with the analysis of the 02.E10 isolate, HCV uses
additional and complex mechanisms to escape from neutraliz-
ing antibodies to conserved epitopes, but with a cost in repli-
cation fitness. This variant was resistant to neutralization by all
domain B antibodies as well as AP33, a broadly neutralizing
antibody recognizing a linear epitope on E2 (35). However,
02.E10 HCVpp infectivity was reduced by over 90% compared
with the level for H77c. Of the five unique 02.E10 mutations at
residues 444, 446, 482, 501, and 506 in E2, in comparison to
what was found for H77c and earlier H variants, the mutations
at residues 501 and 506 were found to synergistically affect
infectivity. With N501S and A506V substitutions in E2 of the
02.E10 variant, the HCVpp infectivity was nearly restored to
the same level as that for H77c HCVpp. An alignment of these
five amino acids on E2 with other HCV sequences in a national
database (http://hcv.lanl.gov/) indicated that residue 506 is at
100% conservation in genotypes 1a, 2a, 3, 4, 5, and 6 but has
0.3% (V to M) and 3.7% (V to F) variations in genotypes 1b
and 2b, respectively. As expected when V was replaced by F,
H77c HCVpp bearing V506F E2 dramatically decreased its
infectivity but V506M retained its infectivity (data not shown).
The analysis showed no conservation at residues 444, 446, 482,
and 501. Of note, restoration of infectivity correlated with
improvement of E2 interaction with CD81. The binding affinity
of 02.E10 E2 for CD81 was fourfold less than that of 02.E10
N501S/A506V E2 for CD81, which was similar to that of H77c
E2 for CD81. In summary, mutations at residues 501/506 in-
duce a structural change that compromises virus interaction
with CD81, leading to inefficient virus entry. In contrast to
restoring efficiency of binding to CD81 and infectivity with
N501S/A506V-02.E10 HCVpp, only partial restoration of do-
main B HMAb binding and neutralizing activities were ob-
served. When Y444Q substitution was added to 02.E10 N501S/
A506V, neutralization by domain B antibodies was restored to
levels comparable to those for H77c. This residue is not part of
domain B epitopes, since Q444A substitution in H77c E2 re-
tained normal binding with domain B antibodies and MAb
AP33 (data not shown). This implies that a mutation at residue
444 alone will not affect broadly neutralizing antibodies. Nev-
ertheless, in conjunction with mutations at residues 501 and
506, their combined effect leads to complete escape from
many, if not all, neutralizing antibodies.
The improved AP33 neutralizing activity observed with the
02.E10 HCVpp bearing N501S/A506V E2 is not associated
with an improved antibody binding affinity but is associated
with an improved binding of N501S/A506V E2 to CD81. Re-
storing a more effective entry pathway via CD81 restored the
functional effect of AP33 binding with neutralization. The lack
of improved binding is consistent with the view that residues
501 and 506 are not part of the AP33 epitope. The fact that the
antibody binding affinity of AP33 for 02.E10 is significantly less
than that for H77c suggests that the epitope of this antibody
contains a conformational component. This is consistent with
the observation that residue 655 on E2 could be involved with
the AP33 epitope (12).
Recently, evidence for direct cell-to-cell transmission was
described as an entry pathway for HCV that occurs in the
presence of neutralizing antibodies in a CD81-independent
manner (43, 49, 51, 54). This can serve as yet another mech-
anism by which the virus may escape from neutralizing an-
tibodies. Studies are under way to assess the impact of
mutations at residues 501 and 506 in the HCVcc system for
cell-to-cell transmission. This should provide additional in-
sights into whether residue 501/506 mutations decreasing
entry via receptor-mediated endocytosis also affect cell-to-
cell spread. In conclusion, the findings in this study suggest
that the location of the mutation at residue 506 in the
02.E10 variant caused a structural change on E2 that dis-
torts the binding of neutralizing antibodies to a cluster of
overlapping conformational epitopes, domain B, containing
residues that are also contact residues for binding of HCV
E2 to CD81. A mutation at this residue could then exacer-
bate the effects of other mutations, e.g., at residue 444, that
by themselves would have minimum or no effect on this
cluster of conformational epitopes. But at the same time,
the disadvantage is a lowered efficiency of virus binding to
CD81 that compromises the virus entry, leading to lower
infectivity. One can speculate from these analyses that dur-
ing the chronic phase of HCV infection and in the presence
of broadly neutralizing serum antibodies, a mutation at res-
idue 506 and other mutations that are not part of an anti-
body binding epitope work in concert to provide a new
mechanism of escape from broadly neutralizing antibodies
to a highly immunogenic region on HCV E2 containing
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multiple overlapping neutralization epitopes, but at a sub-
stantial cost in viral fitness. While the chronology of the
patient H samples is appealing, for some, where we have
only a few variants to analyze, one could make the argument
that the differences that we are seeing in some cases may
represent variation in the population rather than time-de-
pendent selection.
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